Recent AXSM News
- Axsome Therapeutics Recognizes Mental Health Month • GlobeNewswire Inc. • 05/07/2026 11:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/05/2026 09:55:09 PM
- Form 144/A - Report of proposed sale of securities: [Amend] • Edgar (US Regulatory) • 05/05/2026 09:54:01 PM
- Axsome Therapeutics to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 05/05/2026 11:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/04/2026 09:43:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/04/2026 09:04:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/04/2026 11:07:33 AM
- Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/04/2026 11:00:00 AM
- Axsome Therapeutics Hosts AUVELITY® FDA Approval Investor Event Featuring Expert Thought Leader • GlobeNewswire Inc. • 05/01/2026 11:15:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 09:19:05 PM
- Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease • GlobeNewswire Inc. • 04/30/2026 06:06:04 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/24/2026 09:02:38 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/24/2026 09:01:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/24/2026 01:02:45 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/24/2026 01:01:34 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/24/2026 01:00:44 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/24/2026 01:00:20 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/22/2026 08:03:36 PM
- Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4 • GlobeNewswire Inc. • 04/08/2026 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/01/2026 11:05:09 AM
- Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions • GlobeNewswire Inc. • 04/01/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2026 12:10:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2026 12:10:06 AM
